64330-83-2

Usage

Uses

Used in Industrial Applications:
1-(2-hydroxyethyl)pyridin-2(1H)-one is used as a chelating agent for its ability to bind metal ions and form stable complexes. This property is particularly useful in the production of metalworking fluids, detergents, and water treatment processes, where it helps to improve the efficiency and performance of these products.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 1-(2-hydroxyethyl)pyridin-2(1H)-one is utilized to enhance the dissolution and absorption of certain drugs. Its chelating properties allow for better drug delivery and bioavailability, making it a valuable component in the development of new medications and drug formulations.

Upstream product

• 343269-67-0 1-(2-hydroxy-ethyl)-1H-pyridin-2-one-imine 
• 34941-69-0 1-(2-hydroxyethyl)pyridinium chloride 
• 75-21-8 oxirane 
• 142-08-5 2-hydroxypyridin 
• 504-29-0 2-aminopyridine 
• 56446-64-1 2-(pyridine-2-yloxy)ethan-1-ol 
• 142-08-5 2-Pyridone 
• 540-51-2 2-bromoethanol 

Downstream Products

• 51323-39-8 1-(2-chloro-ethyl)-1H-pyridin-2-one 

Relevant academic research and scientific papers

Synthetic access to new pyridone derivatives through the alkylation reactions of hydroxypyridines with epoxides

General methods for the preparation of a variety of pyridone and oxypyridine derivatives are described. 2-,3-,4-Hydroxy pyridine and 2-pyridinemethanol were alkylated with ethylene-, propylene-, and stryrene-oxide and epichlorohydrin in the presence of di

Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance

Phospholipase D (PLD) is a phospholipase enzyme responsible for hydrolyzing phosphatidylcholine into the lipid signaling molecule, phosphatidic acid, and choline. From a therapeutic perspective, PLD has been implicated in human cancer progression as well as a target for neurodegenerative diseases, including Alzheimer's. Moreover, knockdown of PLD rescues the ALS phenotype in multiple Drosophila models of ALS (amyotrophic lateral sclerosis) and displays modest motor benefits in an SOD1 ALS mouse model. To further validate whether inhibiting PLD is beneficial for the treatment of ALS, a brain penetrant small molecule inhibitor with suitable PK properties to test in an ALS animal model is needed. Using a combination of ligand-based drug discovery and structure-based design, a dual PLD1/PLD2 inhibitor was discovered that is single digit nanomolar in the Calu-1 cell assay and has suitable PK properties for in vivo studies. To capture the in vivo measurement of PLD inhibition, a transphosphatidylation pharmacodynamic LC-MS assay was developed, in which a dual PLD1/PLD2 inhibitor was found to reduce PLD activity by 15-20-fold.

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

Intramolecular Photocycloadditions of 1-(ω-Alkenyl)-2-pyridones Possessing an Ester Group on the Olefinic Carbon Chain

Photochemical reactions of three kinds of 1-(ω-alkenyl)-2-pyridones 1-8 were investigated.Photosensitized cyloadditions of 1-(ω-alkenyl)-2-pyridones and 1,3-bis(ω-alkenyl)-2-pyridone 2-6 afforded intramolecular cycloadducts across the 5,6-bonds of the 2-pyridones to give the tricyclic lactams 14-18: the additions were site-, regio-, and stereospecific.The yields of the adducts diminished in proportion to increased side-chain length.The one possessing the shortest alkenyl group, 1, and the 1--2-pyridones 7 and 8, however, gave no products.On the other hand, direct irradiation of 3 afforded a bicyclic lactam 19.The intramolecular cycloaddition mechanism was discussed in terms of the excited state of 2-pyridone, as calculated by MNDO-CI method.